Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.
about
Structural Basis of Targeting the Exportin CRM1 in CancerMan's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma?Optogenetic control of nuclear protein export.A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the NucleusVerdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.Atomic basis of CRM1-cargo recognition, release and inhibitionThe immunosignature of canine lymphoma: characterization and diagnostic applicationNucleo-cytoplasmic transport as a therapeutic target of cancerPreclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin LymphomaBiologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic backgroundExpression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells.Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis.Defining the Value of a Comparative Approach to Cancer Drug Development.Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition?Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.Selective inhibitors of nuclear export (SINE) in hematological malignancies.Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models.Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients.CRM1 Inhibitors for Antiviral Therapy.Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer.Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination.TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia.Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma
P2860
Q26781513-E432FB6C-5D26-464A-884B-C63F15E3B973Q27027137-5647D11B-F110-40A9-A971-96B5FD920BDDQ27333329-0187E38E-BCB3-4A18-ABE6-C81E3C6950FCQ28577939-6AE07454-3308-40F7-94F5-4E85A8EBFBCBQ30363986-9A14DCCA-3FC7-4BEB-9EEB-7D18B8EC34B7Q33940712-3CDEBC1B-3B71-4E00-9E63-B30E7DF95876Q34208766-F4FF2AE6-CD1C-4B48-AEBD-9EE3CF60A501Q34452108-CE6CB960-4BD5-44AB-8646-465724133852Q34534572-F89D7E2E-00A7-4BAA-BECB-7292167E2D01Q35206543-E1F5805B-78EA-47FB-A153-FB72D58C9A56Q35777971-5A5952EB-38DC-4C1A-971F-0FF510B5A6A2Q35920569-ACA9B1B0-66E8-4543-AC4D-368B637DE0E4Q36034972-F518D51A-F890-4814-8DF7-5F533774E395Q36106299-AB0F3945-4776-48AE-A1E1-248E166ED3ABQ36489494-29D7B0A0-D715-437A-B946-0A9C9231B6A4Q37181752-15D5D39D-B5E5-4612-8EA4-9ADB0F61278DQ37417714-BE3B0DBA-9AB6-42E1-86F5-BF56D8FE0AC7Q38222341-297AD301-4B53-4498-B3A4-B9C321BBE43FQ38260357-FF4AAC43-15D9-41D2-99EF-B992881E4B6EQ38368605-21A0663C-725E-47C5-8763-D7F6FBF4E306Q38616707-7DFB2E08-962E-45D4-BECD-F73269AEF2EEQ38834470-884C2634-2797-4970-8E20-10160F5817C8Q39431526-7F9F9613-D54B-4A75-8A2B-2370A0D5301FQ45070681-4D715C44-1A06-4F16-B279-592A7FE248EDQ47549703-129915DC-C73E-4906-A15C-85A7D9895DF3Q48120081-B6533DA1-BD3A-4C14-9294-6FCE68296317Q49164320-65AA5101-12D2-4662-AB24-F63EBBAA8B2FQ53106935-52B3A93F-1956-40E5-9324-D3140BF28A88Q55085029-CFE609BB-C0AF-4AD0-9D75-6B11F188B1B4Q58707427-E3C11F59-4CEB-467A-84A7-09DCEBB18AE4
P2860
Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Preclinical evaluation of the ...... r: results of a phase I study.
@ast
Preclinical evaluation of the ...... r: results of a phase I study.
@en
type
label
Preclinical evaluation of the ...... r: results of a phase I study.
@ast
Preclinical evaluation of the ...... r: results of a phase I study.
@en
prefLabel
Preclinical evaluation of the ...... r: results of a phase I study.
@ast
Preclinical evaluation of the ...... r: results of a phase I study.
@en
P2093
P2860
P1433
P1476
Preclinical evaluation of the ...... r: results of a phase I study.
@en
P2093
Antonella Borgatti
Cheryl A London
Daisuke Ito
Dilara McCauley
Heather Wilson
Jean-Richard Saint-Martin
Kiersten Jensen
Luis Feo Bernabe
Michael Kauffman
Michael L Pennell
P2860
P304
P356
10.1371/JOURNAL.PONE.0087585
P407
P577
2014-02-04T00:00:00Z